We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

HD18 for Advanced Stages in Hodgkins Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00515554
First Posted: August 13, 2007
Last Update Posted: November 8, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Prof. Dr. Andreas Engert, University of Cologne
August 10, 2007
August 13, 2007
November 8, 2016
May 2008
June 2020   (Final data collection date for primary outcome measure)
Progression Free Survival [ Time Frame: 5 years ]
Progression Free Survival
Complete list of historical versions of study NCT00515554 on ClinicalTrials.gov Archive Site
  • Overall Survival [ Time Frame: 5 years ]
  • acute toxicity [ Time Frame: 5 years ]
  • late toxicity [ Time Frame: 5 years ]
  • CR-rate [ Time Frame: 5 years ]
Overall Survival acute and late toxicity CR-rate
Not Provided
Not Provided
 
HD18 for Advanced Stages in Hodgkins Lymphoma
Not Provided

This study is designed to test:

  1. in patients with negative positron-emission tomography (PET) after 2 cycles of BEACOPPesc chemotherapy: whether the number of cycles can be reduced without compromising progression free survival (PFS) (2 further cycles vs. 6 further cycles)
  2. for patients with positive PET after 2 cycles: whether intensifying BEACOPPesc chemotherapy by adding Rituximab improves PFS.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Hodgkins Lymphoma
  • Drug: Rituximab
    addition of Rituximab to BEACOPP escalated
  • Drug: BEACOPP escalated
    chemotherapy with BEACOPP escalated
  • Active Comparator: A
    8 cycles BEACOPPesc
    Intervention: Drug: BEACOPP escalated
  • Experimental: B
    8 cycles BEACOPPesc plus rituximab
    Interventions:
    • Drug: Rituximab
    • Drug: BEACOPP escalated
  • Active Comparator: C
    8 cycles BEACOPPesc
    Intervention: Drug: BEACOPP escalated
  • Experimental: D
    4 cycles BEACOPPesc
    Intervention: Drug: BEACOPP escalated
Sauer M, Plütschow A, Jachimowicz RD, Kleefisch D, Reiners KS, Ponader S, Engert A, von Strandmann EP. Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma. Am J Hematol. 2013 Feb;88(2):113-5. doi: 10.1002/ajh.23361. Epub 2012 Dec 8.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
1500
December 2020
June 2020   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Hodgkin Lymphoma (histologically proven)
  • CS (PS) IIB with one or both of the risk factors:

    • bulky mediastinal mass (> 1/3 of maximum transverse thorax diameter)
    • extranodal involvement
  • CS (PS) III, IV
  • Written informed consent

Exclusion Criteria:

  • Leucocytes < 3000/µl
  • Platelets < 100000/µl
  • Hodgkin´s lymphoma as "composite lymphoma"
  • Activity index (WHO) < grade 2
Sexes Eligible for Study: All
18 Years to 60 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00515554
HD18
Yes
Not Provided
Not Provided
Prof. Dr. Andreas Engert, University of Cologne
University of Cologne
Not Provided
Principal Investigator: Andreas Engert, Prof. University of Cologne
University of Cologne
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP